Lv31
294 积分 2024-03-07 加入
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
38分钟前
待确认
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
2个月前
已完结
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
2个月前
已完结
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
3个月前
已完结
Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults
5个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
5个月前
已完结
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
5个月前
已完结
Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy
5个月前
已完结
The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer—A Literature Review
5个月前
已完结
Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives
5个月前
已完结
皖公网安备34019202002308
